Monopar Therapeutics Inc. (MNPR)

Market Cap	272.44M
Revenue (ttm)	n/a
Net Income (ttm)	-15.59M
Shares Out	6.11M
EPS (ttm)	-4.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,264
Open	42.94
Previous Close	41.47
Day's Range	42.79 - 42.94
52-Week Range	1.72 - 54.30
Beta	1.02
Analysts	Strong Buy
Price Target	59.50 (+33.5%)
Earnings Date	May 8, 2025

About MNPR

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNP...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 19, 2019
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: MNPR
• Website: https://www.monopartx.com

Analyst Forecast

According to 5 analysts, the average rating for MNPR stock is "Strong Buy." The 12-month stock price forecast is $59.5, which is an increase of 33.50% from the latest price.

Price Target

$59.5

(33.50% upside)

Analyst Consensus: Strong Buy